Key facts
- Allyx Therapeutics’s last known valuation is $32.3M (Feb 2023).
- It has raised $13.2M across 4 recorded rounds; the latest was Early Stage VC ($26.4M) in May 2026.
- Notable investors include National Institutes of Health, Connecticut Innovations, Bristol-Myers Squibb, Spring Mountain Capital, Elm Street Ventures — 10 tracked in total.
- Allyx Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently Feb 2023 ($2.3M sold to 11 investors).
- Status: Privately Held (backing).
Investors
10- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Allyx Therapeutics
Funding rounds
4 roundsAbout Allyx Therapeutics
Developer of a therapeutic drug designed to reverse neurodegeneration. The company's drug is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to administer a drug capable of delivering a disease-modifying approach and preserving cognition in patients.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2018
- Employees
- 5
- Website
- allyxthera.com/
- Ownership
- Privately Held (backing)
Allyx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allyx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allyx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.